Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Back
Share this video  

iwNHL 2015 | iwNHL 2015 roundtable: Day 2 highlights – PI3K inhibitors

John Gribben and Wyndham Wilson • 3 Oct 2015
iwNHL 2015
Non-Hodgkin Lymphoma Duvelisib Idelalisib

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They review the clinical development of inhibitors targeting the phosphoinositide 3-kinase (PI3K) pathway, as single agents and in combination with other therapies, for the treatment of patients with non-Hodgkin lymphoma.

More from John Gribben

2:42
Investigating the treatment preferences of physicians in R/R follicular lymphoma
John Gribben • 9 Dec 2023
1:20
Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort
John Gribben • 9 Dec 2023
1:04
The future of CLL therapy
John Gribben • 9 Dec 2023
Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023

More from Wyndham Wilson

4:17
Ibrutinib in DLBCL: revelations from further analysis of PHOENIX
Wyndham Wilson • 2 Jul 2019
1:12
Liquid biopsy to measure MRD
Wyndham Wilson • 2 Jul 2019
2:30
ViPOR regimen for R/R B-cell lymphoma
Wyndham Wilson • 2 Jul 2019
2:49
Liquid biopsy making strides forward in NHL: detection of ctDNA and mutations
Wyndham Wilson • 2 Jul 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals